Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2406026 | 0.86 | — | — | |
| SCHEMBL28997912 | 0.83 | KDM1A (0.57) | — | |
| SCHEMBL5216740 | 0.83 | — | — | |
| SCHEMBL5204617 | 0.83 | — | — | |
| SCHEMBL26154082 | 0.82 | — | — | |
| SCHEMBL8347802 | 0.80 | MGLL (0.47) | NPC1ALDH1A1TP53MAPTTSHR | |
| SCHEMBL4688897 | 0.79 | MGLL (0.46) | NPC1ALDH1A1TP53MAPTTSHR | |
| SCHEMBL14197111 | 0.76 | TP53 (0.53) | NPC1ALDH1A1TP53MAPTTSHR | |
| SCHEMBL4882624 | 0.76 | TP53 (0.53) | NPC1ALDH1A1TP53MAPTTSHR | |
| SCHEMBL8348584 | 0.76 | MGLL (0.49) | NPC1ALDH1A1TP53MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107540625-B | Preparation method of linezolid | 正大天晴药业集团股份有限公司 | 2021-06-25 | — | — | CN | claimed |
| CN-121698825-A | Synthesis method of high-purity N-carbobenzoxy-3-fluoro-4-morpholinylaniline | 河北国龙制药有限公司 | 2026-03-20 | — | — | CN | disclosed |
| CN-121698825-A | Synthesis method of high-purity N-carbobenzoxy-3-fluoro-4-morpholinylaniline | 河北国龙制药有限公司 | 2026-03-20 | — | — | CN | disclosed |
| CN-113045509-B | Industrial production method of linezolid | 上海翰森生物医药科技有限公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-113045509-A | Industrial production method of linezolid | 上海翰森生物医药科技有限公司 | 2021-06-29 | — | — | CN | disclosed |
| CN-107540625-B | Preparation method of linezolid | 正大天晴药业集团股份有限公司 | 2021-06-25 | — | — | CN | disclosed |
| CN-107540625-B | Preparation method of linezolid | 正大天晴药业集团股份有限公司 | 2021-06-25 | — | — | CN | disclosed |
| CN-107698533-B | Method for preparing linezolid | 浙江海翔川南药业有限公司 | 2021-03-26 | — | — | CN | disclosed |
| US-9012631-B2 | 1,3-oxazolidine-2-one-like compound, preparation method and uses thereof | YABANG PHARMACEUTICAL CO., LTD (CN) | 2015-04-21 | — | — | US | disclosed |
| CN-102977056-B | Synthesis method of N-carbobenzoxy-3-fluoro-4-morpholinylaniline | SHENZHEN MAIN LUCK PHARMACEUTICALS INC | 2014-11-26 | — | — | CN | disclosed |
| US-8038543-B2 | Golf swing training device | CAPESIUS DEAN C | 2011-10-18 | — | — | US | disclosed |
| WO-2011114210-A2 | PROCESSES FOR THE PREPARATION OF LINEZOLID | JUBILANT LIFE SCIENCES LIMITED (IN) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011077310-A1 | PROCESS FOR THE PREPARATION OF LINEZOLID | ALEMBIC LIMITED (IN) | 2011-06-30 | — | — | WO | disclosed |
| EP-1380121-B1 | PROCESS TO PREPARE OXAZOLIDINONES | PHARMACIA & UPJOHN CO LLC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-7087784-B2 | Process to prepare oxazolidinones | PHARMACIA & UPJOHN (US) | 2006-08-08 | — | — | US | disclosed |
| US-6887995-B2 | Process to prepare oxazolidinones | PHARMACIA & UPJOHN COMPANY (US) | 2005-05-03 | — | — | US | disclosed |
| US-20040220407-A1 | Process to prepare oxazolidinones | PERRAULT WILLIAM R | 2004-11-04 | — | — | US | disclosed |
| EP-1380121-A2 | PROCESS TO PREPARE OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20020169312-A1 | Process to prepare oxazolidinones | PHARMACIA & UPJOHN COMPANY | 2002-11-14 | — | — | US | disclosed |
| WO-2002085849-A2 | PROCESS TO PREPARE OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220407-A1 | Process to prepare oxazolidinones | CYP3A5, OXA1L, CYP3A4 | NPC1 4106/4885ALDH1A1 188/4885TP53 4526/4885 |
| US-20020169312-A1 | Process to prepare oxazolidinones | CYP3A5, OXA1L, CYP3A4 | NPC1 4106/4885ALDH1A1 188/4885TP53 4526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.